HSBC Holdings
BBIO icon

HSBC Holdings’s BridgeBio Pharma BBIO Stock Holding History

HSBC Holdings’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.43M Buy
32,708
+19,043
+139% +$1.38M ﹤0.01% 1437
2025
Q4 		$1.05M Buy
+13,665
New +$897K ﹤0.01% 1911
2025
Q3 		– Sell
-6,292
Closed -$271K – 2727
2025
Q2 		$271K Sell
6,292
-9,999
-61% -$364K ﹤0.01% 2518
2025
Q1 		$557K Sell
16,291
-11,957
-42% -$403K ﹤0.01% 2021
2024
Q4 		$784K Buy
28,248
+4,646
+20% +$120K ﹤0.01% 1932
2024
Q3 		$603K Buy
+23,602
New +$620K ﹤0.01% 1917
2024
Q2 		– Sell
-11,849
Closed -$366K – 2946
2024
Q1 		$366K Buy
+11,849
New +$403K ﹤0.01% 2287
2023
Q1 		– Sell
-43,184
Closed -$317K – 2687
2022
Q4 		$317K Sell
43,184
-611
-1% -$5.85K ﹤0.01% 2516
2022
Q3 		$456K Buy
43,795
+6,509
+17% +$67.6K ﹤0.01% 2216
2022
Q2 		$338K Buy
37,286
+9,304
+33% +$77.8K ﹤0.01% 2570
2022
Q1 		$288K Buy
+27,982
New +$287K ﹤0.01% 2775
2021
Q4 		– Sell
-21,899
Closed -$1.06M – 3252
2021
Q3 		$1.06M Buy
21,899
+17,655
+416% +$946K ﹤0.01% 1849
2021
Q2 		$261K Sell
4,244
-1,144
-21% -$65.3K ﹤0.01% 2604
2021
Q1 		$329K Sell
5,388
-3,369
-38% -$220K ﹤0.01% 2230
2020
Q4 		$619K Buy
+8,757
New +$422K ﹤0.01% 2038

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HSBC Holdings's BBIO Position: Q1 2026 in Review

HSBC Holdings increased its BridgeBio Pharma (BBIO) stake by 139% in Q1 2026, buying an estimated $1.38M and bringing the position to 32,708 shares worth $2.43M. The position accounts for ﹤0.01% of the portfolio, ranked #1437.

HSBC Holdings first reported a position in BBIO in Q4 2020 and has held it in 15 quarters since. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • HSBC Holdings held 32,708 shares of BridgeBio Pharma worth $2.43M as of Q1 2026.
  • HSBC Holdings bought 19,043 BridgeBio Pharma shares in Q1 2026, an estimated $1.38M.
  • BridgeBio Pharma made up ﹤0.01% of HSBC Holdings's portfolio in Q1 2026, its #1437 holding.
  • HSBC Holdings first reported a position in BridgeBio Pharma in Q4 2020 and has held it in 15 quarters since.
  • 457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.